Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2566 studies found for:    cyclophosphamide
Show Display Options
Rank Status Study
1 Recruiting Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy
Condition: Hematologic Malignancies
Intervention: Drug: Cyclophosphamide
2 Completed
Has Results
Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients
Conditions: Burkitt's Lymphoma;   Lymphoblastic Lymphoma;   Acute Lymphoblastic Leukemia
Interventions: Drug: Clofarabine;   Drug: Cyclophosphamide
3 Active, not recruiting Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T
Condition: HIV
Intervention: Genetic: SB-728-T
4 Recruiting High-dose Cyclophosphamide for Severe Refractory Crohn Disease
Conditions: Crohn's Disease;   Crohn Disease
Intervention: Drug: High-dose Cyclophosphamide
5 Completed Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis
Conditions: SLE;   Lupus Nephritis;   Renal Insufficiency;   End-stage Renal Disease
Interventions: Drug: Tacrolimus;   Drug: cyclophosphamide
6 Terminated Cyclophosphamide Drug Interaction Study In Cancer Patients
Conditions: Nausea and Vomiting, Chemotherapy-Induced;   Cancer
Interventions: Drug: Oral GW679769;   Drug: IV Cyclophosphamide 500-700mg/m2
7 Recruiting Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Oprozomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Cyclophosphamide
8 Recruiting Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
Condition: Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Rituximab;   Drug: Sapacitabine
9 Completed Study of Bortezomib in Combination With Cyclophosphamide and Rituximab
Conditions: Mantle Cell Lymphoma;   Lymphoma
Interventions: Drug: Bortezomib;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: G-CSF
10 Not yet recruiting Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: Sorafenib;   Drug: Cyclophosphamide;   Drug: Topotecan
11 Completed Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Fludarabine Phosphate;   Drug: Cyclophosphamide;   Drug: Rituximab
12 Unknown  Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention: Drug: sorafenib and cyclophosphamide
13 Active, not recruiting Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus
Condition: Pemphigus
Intervention: Drug: Rituximab and Cyclophosphamide IV
14 Recruiting Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide, endoxan, prednisone;   Drug: lenalidomide, endoxan, prednisone
15 Active, not recruiting Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas
Condition: Pancreatic Cancer
Interventions: Drug: Cyclophosphamide;   Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine;   Radiation: Stereotactic Body Radiation (SBRT);   Drug: FOLFIRINOX
16 Active, not recruiting Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia
Condition: Aplastic Anemia
Intervention: Drug: cyclophosphamide,cyclosporine A
17 Recruiting Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children
Conditions: Renal Insufficiency;   Infection
Interventions: Drug: Low-dose intravenous cyclophosphamide;   Drug: High-dose intravenous cyclophosphamide
18 Unknown  Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide (AC)
19 Completed
Has Results
Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Etoposide;   Drug: Cyclophosphamide
20 Active, not recruiting Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
Conditions: Hodgkin's Disease;   Lymphoma
Intervention: Drug: rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years